Lupin receives USFDA nod for Lorazepam Oral Concentrate

Drug firm Lupin today said it has received US health regulator's approval to market its generic Lorazepam Oral Concentrate, used for treating anxiety disorders, in the American market.

Lupin Pharmaceuticals Inc, a subsidiary of Lupin, has received final approval from US Food and Drug Administration (USFDA) for its Lorazepam Oral Concentrate USP, Lupin Ltd said in a statement.

The Mumbai-headquartered firm's product is a generic version of Roxane Inc's Lorazepam Intensol and is indicated for the management of anxiety disorders or for the short- term relief of the symptoms of anxiety or anxiety associated with depressive symptoms, it added.

According to IMS MAT September 2012 sales data, Lorazepam Oral Concentrate had annual US sales of nearly $10.7 million.

Lupin scrip closed at Rs 594 on the BSE, down 0.21 per cent from its previous close.

EDITORIAL OF THE DAY

  • The solution to tackling recurrent droughts is in managing consumption of water, not its overuse

    A staggering 33 crore people or more than a quarter of the country’s population are in the grip of drought and consequently, face drinking water sho

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Tushar Gandhi

An unexplored side of rural enterprise

What is rural enterprise? Ask this qu­estion and 9 out ...

Kuruvilla Pandikattu

Black and white of morality

Would you kill one innocent person to save five? Choose ...

Shona Adhikari

Let's head to Bangalore & catch up on art

Bangalore art scene is bang in the middle of news, ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture